Philipp Badorrek

Nikolai Fuchs Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.

Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.

Journal: Pulmonary pharmacology & therapeutics

Published: May 19, 2026

Threshold Concentration of Ragweed Pollen for Inducing Allergic Symptoms: Initial Data Using an Allergen Challenge Chamber.

Threshold Concentration of Ragweed Pollen for Inducing Allergic Symptoms: Initial Data Using an Allergen Challenge Chamber.

Journal: International archives of allergy and immunology

Published: November 28, 2025

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD.

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD.

Journal: ERJ open research

Published: September 18, 2025

Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial.

Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial.

Journal: Pulmonary pharmacology & therapeutics

Published: February 03, 2025

Determining the Threshold Concentration of Birch Pollen for Inducing Allergic Symptoms Using an Allergen Challenge Chamber.

Determining the Threshold Concentration of Birch Pollen for Inducing Allergic Symptoms Using an Allergen Challenge Chamber.

Journal: International archives of allergy and immunology

Published: January 03, 2025

Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites.

Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites.

Journal: The journal of allergy and clinical immunology. Global

Published: August 29, 2024

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Journal: Clinical and translational science

Published: May 16, 2024

RLS-0071, a novel anti-inflammatory agent, significantly reduced inflammatory biomarkers in a randomised human evaluation of mechanisms and safety study.

RLS-0071, a novel anti-inflammatory agent, significantly reduced inflammatory biomarkers in a randomised human evaluation of mechanisms and safety study.

Journal: ERJ open research

Published: January 03, 2024

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.

Journal: ERJ open research

Published: September 29, 2023

Correction to: Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.

Correction to: Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.

Journal: Clinical pharmacokinetics

Published: August 05, 2023

Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.

Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.

Journal: Clinical pharmacokinetics

Published: June 01, 2023

Sodium Chloride versus Lactose as a Carrier for House Dust Mite Allergen in Allergen Chamber Studies: A Clinical Study to Assess Noninferiority.

Sodium Chloride versus Lactose as a Carrier for House Dust Mite Allergen in Allergen Chamber Studies: A Clinical Study to Assess Noninferiority.

Journal: International archives of allergy and immunology

Published: April 20, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026